Department of Psychiatry
Penn Behavioral Health

Center for Studies of Addiction

subpage feature

Brain-Behavioral Vulnerabilities Laboratory

 

Clinical Studies


Click on the links below to find out more about the research studies for which you may qualify:

NICOTINE STUDIES

Study Name: Effects of Varenicline (Chantix) on Smoking Behavior (VSMK)

Diagnosis or Problem: Nicotine dependence

Study Summary: The purpose of our research is to study a medication that may help you quit smoking.  We also want to learn more about how this medication impacts your response to smoking cues, or reminders, in your environment that may cause you to crave cigarettes. We will be studying the FDA-approved anti-smoking medication called varenicline, also known as Chantix. In this study, the medication is being compared to a placebo, which is a pill that looks like the medication but has no active ingredients. If you qualify for the study, you have a 1 in 2 (50%) chance of receiving the medication. This means that half the people will be taking medication, and half will be taking a pill that has no medication in it.

Age: 18-60 years

Study Involves: Varenicline or placebo (double-blind), 2 fMRI scans, plus weekly medication monitoring by the medical staff

Duration: 8 weeks of treatment (including 2 fMRI scans) plus 1 week of follow-up

Study Status: Active - recruiting patients

Contact Information:
Telephone: 1-215-222-3200 x199
Jamison :  langguth@mail.med.upenn.edu
Melanie: mmaron@mail.med.upenn.edu

 

Study Name: Baclofen effects on brain and behavior in cigarette smokers (BAC)

Diagnosis or Problem: Nicotine dependence

Study Summary: The purpose of our research is to study a medication that may help you quit smoking.  We also want to learn more about how this medication impacts your response to smoking cues, or reminders, in your environment that may cause you to crave cigarettes. In this study, the medication (baclofen) is being compared to a placebo, which is a pill that looks like the medication but has no active ingredients. If you qualify for the study, you have a 1 in 2 (50%) chance of receiving the medication; if you don’t receive the medication, you’ll receive the placebo. This study is double-blinded.  That simply means that neither you, nor any member of the research team, will know whether you are receiving the medication or the placebo; this is an important way of studying the effectiveness of the medication without biasing our results in any way. Given that genetics play a large role in smoking behavior, we are also studying some genes that are involved in smoking.

Age: 18-60 years

Study Involves: Baclofen or placebo (double-blind), 2 fMRI scans, plus weekly medication monitoring by our medical staff.

Duration: 8 weeks of treatment (including 2 fMRI scans) plus 1 week of follow-up

Study Status: Active - recruiting patients

Contact Information: 
Telephone: 1-215-222-3200 x204
Shannon: shkel@mail.med.upenn.edu
Melanie: mmaron@mail.med.upenn.edu





< back to BBV Clinical Trials page